MX2019006823A - Tratamiento de una enfermedad del tracto gastrointestinal con inhibidor de interleucina-12/interleucina-23 (il-12/il-23) liberado usando un dispositivo ingerible. - Google Patents
Tratamiento de una enfermedad del tracto gastrointestinal con inhibidor de interleucina-12/interleucina-23 (il-12/il-23) liberado usando un dispositivo ingerible.Info
- Publication number
- MX2019006823A MX2019006823A MX2019006823A MX2019006823A MX2019006823A MX 2019006823 A MX2019006823 A MX 2019006823A MX 2019006823 A MX2019006823 A MX 2019006823A MX 2019006823 A MX2019006823 A MX 2019006823A MX 2019006823 A MX2019006823 A MX 2019006823A
- Authority
- MX
- Mexico
- Prior art keywords
- disease
- gastrointestinal tract
- treatment
- ingestible device
- inhibitor released
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 210000001035 gastrointestinal tract Anatomy 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
- A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B10/00—Other methods or instruments for diagnosis, e.g. instruments for taking a cell sample, for biopsy, for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements
- A61B10/0045—Devices for taking samples of body liquids
- A61B2010/0061—Alimentary tract secretions, e.g. biliary, gastric, intestinal, pancreatic secretions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/07—Endoradiosondes
- A61B5/073—Intestinal transmitters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0097—Micromachined devices; Microelectromechanical systems [MEMS]; Devices obtained by lithographic treatment of silicon; Devices comprising chips
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/525—Tumor necrosis factor [TNF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5412—IL-6
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/545—IL-1
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/55—IL-2
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/555—Interferons [IFN]
- G01N2333/57—IFN-gamma
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
Abstract
Esta descripción presenta métodos y composiciones para tratar enfermedades del tracto gastrointestinal con un inhibidor de IL-12/IL-23. En particular, los medicamentos son administrados en la proximidad de sitios de la enfermedad usando dispositivos ingeribles que pueden liberar el fármaco en una manera controlada.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662434348P | 2016-12-14 | 2016-12-14 | |
US201762478744P | 2017-03-30 | 2017-03-30 | |
US201762545188P | 2017-08-14 | 2017-08-14 | |
US201762583797P | 2017-11-09 | 2017-11-09 | |
PCT/US2017/066474 WO2018112232A1 (en) | 2016-12-14 | 2017-12-14 | Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor released using an ingestible device |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019006823A true MX2019006823A (es) | 2019-10-21 |
Family
ID=60953956
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019006823A MX2019006823A (es) | 2016-12-14 | 2017-12-14 | Tratamiento de una enfermedad del tracto gastrointestinal con inhibidor de interleucina-12/interleucina-23 (il-12/il-23) liberado usando un dispositivo ingerible. |
Country Status (9)
Country | Link |
---|---|
US (1) | US11597762B2 (es) |
EP (1) | EP3554540B1 (es) |
JP (2) | JP7237834B2 (es) |
KR (1) | KR20190095931A (es) |
CN (2) | CN117045784A (es) |
BR (1) | BR112019011702A2 (es) |
CA (1) | CA3045475A1 (es) |
MX (1) | MX2019006823A (es) |
WO (1) | WO2018112232A1 (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019118778A1 (en) * | 2017-12-14 | 2019-06-20 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a s1p modulator |
JP6611833B2 (ja) * | 2018-01-16 | 2019-11-27 | キヤノン株式会社 | 放射線撮影システム、並びに、カメラ制御装置及びその制御方法 |
EP3810268A1 (en) * | 2018-06-20 | 2021-04-28 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor |
LT3883606T (lt) * | 2018-09-24 | 2023-09-11 | Janssen Biotech, Inc. | Saugus ir veiksmingas opinio kolito gydymo būdas anti-il12/il23 antikūnu |
EP3880836A4 (en) * | 2018-11-15 | 2022-11-16 | Janssen Biotech, Inc. | METHODS AND COMPOSITIONS FOR PREDICTING RESPONSE TO INFLAMMATORY BOWEL DISEASE THERAPY |
CN109350599A (zh) * | 2018-12-12 | 2019-02-19 | 辽宁新高制药有限公司 | 一种用于皮肤念球菌病治疗的喷雾剂 |
WO2020234834A1 (en) | 2019-05-23 | 2020-11-26 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha |
AU2020365589A1 (en) * | 2019-10-18 | 2022-05-19 | Janssen Biotech, Inc. | Safe and effective method of treating ulcerative colitis with anti-IL12/IL23 antibody |
KR102391865B1 (ko) * | 2020-04-03 | 2022-04-27 | 재단법인대구경북과학기술원 | 약물 전달 디바이스 |
CN112731954B (zh) * | 2020-12-25 | 2024-06-21 | 深圳市优必选科技股份有限公司 | 机器人的运动控制方法、装置、机器人及存储介质 |
KR20230132869A (ko) * | 2021-01-29 | 2023-09-18 | 바이오그레일 에이피에스 | 단일 부착부 약물 전달 장치 |
DK180991B1 (en) * | 2021-01-29 | 2022-09-06 | Biograil ApS | Drug delivery device with carrier and insert |
EP4284483A1 (en) * | 2021-01-29 | 2023-12-06 | Biograil APS | Drug delivery device with releasable attachment part |
CN118176034A (zh) * | 2021-10-28 | 2024-06-11 | 柏欧格瑞有限责任公司 | 高剂量药物输送装置 |
WO2024086013A1 (en) * | 2022-10-17 | 2024-04-25 | Rani Therapeutics, Llc | Ustekinumab dosage forms and methods |
CN116027048A (zh) * | 2023-02-06 | 2023-04-28 | 山东中鸿特检生物科技有限公司 | 一种细胞因子风暴综合征诊断试剂盒及其应用 |
Family Cites Families (119)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
IL47062A (en) | 1975-04-10 | 1979-07-25 | Yeda Res & Dev | Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde |
US4281645A (en) | 1977-06-28 | 1981-08-04 | Duke University, Inc. | Method and apparatus for monitoring metabolism in body organs |
US4190328A (en) | 1978-12-01 | 1980-02-26 | Levine Robert A | Process for detection of blood-borne parasites |
JPS5588732A (en) | 1978-12-26 | 1980-07-04 | Olympus Optical Co | Endoscope |
US4665077A (en) | 1979-03-19 | 1987-05-12 | The Upjohn Company | Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
IL85746A (en) | 1988-03-15 | 1994-05-30 | Yeda Res & Dev | Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases |
FI891226A (fi) | 1988-04-28 | 1989-10-29 | Univ Leland Stanford Junior | Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom. |
JP2681061B2 (ja) | 1988-06-08 | 1997-11-19 | ロンドン・ダイアグノスティック・インコーポレーテッド | 検出可能なシグナルのセンシタイザー誘導発生を利用したアッセイ |
WO1990008187A1 (en) | 1989-01-19 | 1990-07-26 | Dana Farber Cancer Institute | Soluble two domain cd2 protein |
JP3472297B2 (ja) | 1989-03-21 | 2003-12-02 | ザ イミューン レスポンス コーポレイション | 特定のt細胞集団の病原性応答により生じる疾患に対するワクチン接種および方法 |
DE69031919T3 (de) | 1989-07-19 | 2005-01-27 | Connetics Corp., Palo Alto | T-zell-rezeptor-peptide als heilmittel für autoimmune und bösartige krankheiten |
US6251581B1 (en) | 1991-05-22 | 2001-06-26 | Dade Behring Marburg Gmbh | Assay method utilizing induced luminescence |
US5279607A (en) | 1991-05-30 | 1994-01-18 | The State University Of New York | Telemetry capsule and process |
US5314805A (en) | 1991-10-28 | 1994-05-24 | Molecular Probes, Inc. | Dual-fluorescence cell viability assay using ethidium homodimer and calcein AM |
US5318557A (en) | 1992-07-13 | 1994-06-07 | Elan Medical Technologies Limited | Medication administering device |
WO1994004678A1 (en) | 1992-08-21 | 1994-03-03 | Casterman Cecile | Immunoglobulins devoid of light chains |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US5853697A (en) | 1995-10-25 | 1998-12-29 | The United States Of America, As Represented By The Department Of Health & Human Services | Methods of treating established colitis using antibodies against IL-12 |
US5763602A (en) | 1996-10-01 | 1998-06-09 | Li; Ying-Syi | Methods of syntheses of phthalocyanine compounds |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
UA67760C2 (uk) | 1997-12-11 | 2004-07-15 | Міннесота Майнінг Енд Мануфакчурінг Компані | Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки |
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
JP2002504689A (ja) | 1998-02-18 | 2002-02-12 | デイド・ベーリング・インコーポレイテッド | 複数の検体の検出において使用するための化学ルミネセンス組成物 |
EP1108435B1 (en) | 1998-08-24 | 2007-01-03 | Chugai Seiyaku Kabushiki Kaisha | Preventives or remedies for pancreatitis containing anti-il-6 receptor antibodies as the active ingredient |
US6331530B1 (en) | 1999-07-13 | 2001-12-18 | The Trustees Of Columbia University In The City Of New York | Hydrophilic carrier for photosensitizers that cleaves when they catalyze the formation of singlet oxygen |
US6703248B1 (en) | 1999-12-15 | 2004-03-09 | Dade Behring Marburg Gmbh | Particles for diagnostic and therapeutic use |
GB9930000D0 (en) | 1999-12-21 | 2000-02-09 | Phaeton Research Ltd | An ingestible device |
US6902734B2 (en) | 2000-08-07 | 2005-06-07 | Centocor, Inc. | Anti-IL-12 antibodies and compositions thereof |
US20030117491A1 (en) | 2001-07-26 | 2003-06-26 | Dov Avni | Apparatus and method for controlling illumination in an in-vivo imaging device |
CA2475516A1 (en) | 2002-03-05 | 2003-09-18 | Aclara Biosciences, Inc. | Multiplex analysis using membrane-bound sensitizers |
US7797033B2 (en) | 2002-04-08 | 2010-09-14 | Smart Pill Corporation | Method of using, and determining location of, an ingestible capsule |
US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
KR20050098277A (ko) * | 2003-01-29 | 2005-10-11 | 이-필 파마 리미티드 | 위장관 내 약물의 능동 송달 |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
US7247711B2 (en) | 2003-05-09 | 2007-07-24 | Centocor, Inc. | IL-23p40 specific antibody |
WO2005000101A2 (en) | 2003-06-12 | 2005-01-06 | University Of Utah Research Foundation | Apparatus, systems and methods for diagnosing carpal tunnel syndrome |
US7402398B2 (en) | 2003-07-17 | 2008-07-22 | Monogram Biosciences, Inc. | Measuring receptor homodimerization |
US20050065441A1 (en) | 2003-08-29 | 2005-03-24 | Arkady Glukhovsky | System, apparatus and method for measurement of motion parameters of an in-vivo device |
JP4445732B2 (ja) | 2003-08-29 | 2010-04-07 | オリンパス株式会社 | 被検体内導入装置および無線型被検体内情報取得システム |
JP2005074031A (ja) | 2003-09-01 | 2005-03-24 | Pentax Corp | カプセル内視鏡 |
AU2004275804A1 (en) | 2003-09-23 | 2005-04-07 | Light Sciences Oncology, Inc. | Conjugates for photodynamic therapy |
US8206285B2 (en) | 2003-12-31 | 2012-06-26 | Given Imaging Ltd. | Apparatus, system and method to indicate in-vivo device location |
EP3269738A1 (en) | 2004-03-24 | 2018-01-17 | Chugai Seiyaku Kabushiki Kaisha | Subtypes of humanized antibody against interleukin-6 receptor |
EP1750676B1 (en) | 2004-05-20 | 2014-07-23 | Biosensors International Group, Ltd. | Ingestible device platform for the colon |
JP4709836B2 (ja) | 2004-05-21 | 2011-06-29 | ギブン イメージング リミテッド | 自律型体内デバイス |
AR051444A1 (es) | 2004-09-24 | 2007-01-17 | Centocor Inc | Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
CN101107038A (zh) * | 2005-01-18 | 2008-01-16 | 皇家飞利浦电子股份有限公司 | 电控胶囊 |
US20080121825A1 (en) * | 2005-01-18 | 2008-05-29 | Koninklijke Philips Electronics, N.V. | Electronically Controlled Capsule For Releasing Radiation |
PL2390267T3 (pl) | 2005-06-07 | 2013-09-30 | Esbatech A Novartis Co Llc | Stabilne i rozpuszczalne przeciwciała hamujące TNF(alfa) |
TR201902033T4 (tr) | 2005-06-30 | 2019-03-21 | Janssen Biotech Inc | Anti-IL-23 antikorları, bileşimleri, yöntemleri ve kullanımları. |
US20070027362A1 (en) | 2005-07-27 | 2007-02-01 | Olympus Medical Systems Corp. | Infrared observation system |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
KR20130108481A (ko) | 2005-08-19 | 2013-10-02 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
JP2009541298A (ja) * | 2006-06-20 | 2009-11-26 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 胃腸障害を処置するための電子カプセル |
RU2009106062A (ru) * | 2006-06-23 | 2010-08-27 | Конинклейке Филипс Электроникс, Н.В. (Nl) | Система доставки медикамента |
US8615284B2 (en) | 2006-09-06 | 2013-12-24 | Innurvation, Inc. | Method for acoustic information exchange involving an ingestible low power capsule |
CN101534711B (zh) | 2006-10-31 | 2012-11-14 | 皇家飞利浦电子股份有限公司 | 用于在胃肠道中释放药物的可吞吃的多喷嘴给药设备的设计 |
WO2008104968A1 (en) * | 2007-02-26 | 2008-09-04 | Duocure, Inc. | Spray administration of compositions including active agents such as peptides to the gastrointestinal tract |
NZ579297A (en) * | 2007-02-28 | 2012-03-30 | Schering Corp | Combination therapy comprising an il-23 antagonist and a cytokine antagonist for treatment of immune disorders |
ES2524345T3 (es) * | 2007-04-04 | 2014-12-05 | Sigmoid Pharma Limited | Composición farmacéutica oral |
JP4932588B2 (ja) | 2007-05-08 | 2012-05-16 | オリンパス株式会社 | 画像処理装置および画像処理プログラム |
US7842144B1 (en) | 2007-06-01 | 2010-11-30 | The United States Of America As Represented By The Secretary Of The Navy | Methods of making double base casting powder |
AU2008304756B8 (en) | 2007-09-26 | 2015-02-12 | Chugai Seiyaku Kabushiki Kaisha | Anti-IL-6 receptor antibody |
RU2490025C2 (ru) | 2007-10-02 | 2013-08-20 | Чугаи Сейяку Кабусики Кайся | Терапевтические средства, используемые против реакции трансплантат против хозяина, содержащие в качестве активного ингредиента ингибитор рецептора интерлейкина-6 |
WO2009046168A1 (en) | 2007-10-02 | 2009-04-09 | Avaxia Biologics, Inc. | Antibody therapy for use in the digestive tract |
EP2254464B1 (en) | 2008-02-18 | 2017-01-04 | Medimetrics Personalized Drug Delivery B.V. | Administration of drugs to a patient |
US8034344B2 (en) | 2008-05-13 | 2011-10-11 | Novimmune S.A. | Anti-IL-6/IL-6R antibodies and methods of use thereof |
CN102124344B (zh) * | 2008-05-16 | 2015-04-01 | 霍夫曼-拉罗奇有限公司 | 生物标记用于评估β7整联蛋白拮抗剂治疗胃肠道炎性病症的用途 |
TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
KR100931946B1 (ko) | 2009-06-10 | 2009-12-15 | 주식회사 인트로메딕 | 캡슐 내시경에 의해 촬영된 이미지 데이터를 저장하고 있는 서버로부터 관심있는 데이터를 우선하여 단말기에 수신하여 확인할 수 있도록 하는 서버-클라이언트 시스템의 이미지 데이터 전송 프로세싱 방법 |
WO2011004395A1 (en) | 2009-07-06 | 2011-01-13 | Intas Biopharmaceuticals Limited | Microemulsion formulation for biologicals |
EP2461746A1 (en) | 2009-08-05 | 2012-06-13 | Tel HaShomer Medical Research Infrastructure and Services Ltd. | Methods and devices for providing information useful in the diagnosis of abnormalities of the gastrointestinal tract |
US9026192B2 (en) | 2009-11-24 | 2015-05-05 | Given Imaging Ltd | Device and method for in vivo imaging |
EP2571573A4 (en) * | 2010-03-17 | 2013-12-04 | Photopill Medical Ltd | PHOTOTHERAPY BY CAPSULE |
DE112012000404T5 (de) | 2011-01-04 | 2014-04-17 | Charitè Universitätsmedizin Berlin | Modulatoren von IL-12 und/oder IL-23 zur Prävention oder Behandlung des Morbus Alzheimer |
CA2821926A1 (en) | 2011-01-07 | 2012-07-12 | Abbvie Inc. | Anti-il-12/il-23 antibodies and uses thereof |
BR112013021863A2 (pt) | 2011-03-03 | 2016-11-22 | Apexigen Inc | anticorpos anti-receptor il-6 e métodos de uso |
EP2623017B1 (en) | 2011-04-01 | 2017-11-08 | Olympus Corporation | Receiving device and capsule endoscope system |
WO2012158648A1 (en) | 2011-05-13 | 2012-11-22 | Massachusetts Institute Of Technology | Method and apparatus for delivering a substance |
US8907081B2 (en) | 2011-05-27 | 2014-12-09 | Sharp Laboratories Of America, Inc. | Long wavelength absorbing porphyrin photosensitizers for dye-sensitized solar cells |
AU2012346861A1 (en) | 2011-11-30 | 2014-06-19 | AbbVie Deutschland GmbH & Co. KG | Methods and compositions for determining responsiveness to treatment with a tnf-alpha inhibitor |
US9795330B2 (en) | 2011-12-15 | 2017-10-24 | Given Imaging Ltd. | Device, system and method for in-vivo detection of bleeding in the gastrointestinal tract |
CN104271028B (zh) | 2011-12-15 | 2017-11-17 | 基文影像公司 | 确定患者的胃肠道随时间的出血曲线的类型的系统 |
WO2013087912A1 (en) | 2011-12-16 | 2013-06-20 | Synthon Biopharmaceuticals B.V. | Compounds and methods for treating inflammatory diseases |
WO2013113326A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
FR2986432B1 (fr) | 2012-02-06 | 2014-03-14 | Univ Lille Ii Droit & Sante | Proteines 28kda gst provenant de schistosomes pour leur utilisation dans le traitement des maladies inflammatoires auto-immunes engendrant une reponse de type th1 et/ou th17 |
WO2013120184A1 (en) | 2012-02-17 | 2013-08-22 | Micropharma Limited | Ingestible medical device |
US9487590B2 (en) | 2012-09-25 | 2016-11-08 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind interleukin-6 receptor and methods of use thereof |
RU2015155590A (ru) | 2013-05-24 | 2017-06-29 | Нестек С.А. | Путеспецифичные маркеры для диагностики синдрома раздраженного кишечника |
US9324145B1 (en) | 2013-08-08 | 2016-04-26 | Given Imaging Ltd. | System and method for detection of transitions in an image stream of the gastrointestinal tract |
EP3049145B1 (en) * | 2013-09-26 | 2020-06-17 | Progenity, Inc. | Delivery capsule with threshold release |
WO2015099749A1 (en) | 2013-12-27 | 2015-07-02 | Capso Vision Inc. | Capsule camera device with multi-spectral light sources |
EP3089994B1 (en) | 2013-12-30 | 2022-05-04 | Epimab Biotherapeutics, Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
WO2015112575A1 (en) | 2014-01-22 | 2015-07-30 | The Board Of Regents Of The University Of Nebraska | Gastrointestinal sensor implantation system |
WO2015183886A1 (en) | 2014-05-30 | 2015-12-03 | Schaeffler Technologies Gmbh & Co. Kg | Torque converter including spherical clutch |
JP6648120B2 (ja) * | 2014-09-25 | 2020-02-14 | プロジェニティ, インコーポレイテッド | 局所化能力を有する電気機械丸薬デバイス |
US9714288B2 (en) | 2014-09-30 | 2017-07-25 | The Regents Of The University Of California | Antisense compounds and uses thereof |
CN104473611B (zh) | 2015-01-19 | 2018-01-30 | 吉林大学 | 具有超声波定位功能的胶囊内窥镜系统 |
US10064544B2 (en) | 2015-01-26 | 2018-09-04 | The Chinese University Of Hong Kong | Endoscopic capsule and endoscopic system |
KR102622281B1 (ko) | 2015-03-31 | 2024-01-08 | 소리소 파마슈티컬스 인크. | 폴리펩티드 |
US10773063B2 (en) | 2015-05-31 | 2020-09-15 | Check-Cap Ltd | Drug delivery capsule |
JP2017012395A (ja) | 2015-06-30 | 2017-01-19 | 富士フイルム株式会社 | 内視鏡システム及び内視鏡システムの作動方法 |
CA3034267A1 (en) | 2016-08-18 | 2018-02-22 | Mitchell Lawrence Jones | Systems for obtaining samples using ingestible devices |
EP3509469A1 (en) | 2016-09-09 | 2019-07-17 | Progenity, Inc. | Electromechanical ingestible device for delivery of a dispensable substance |
CA3036334A1 (en) | 2016-09-09 | 2018-03-15 | Mitchell Lawrence Jones | Systems and methods for extracting a sample from an ingestible device |
US10610104B2 (en) | 2016-12-07 | 2020-04-07 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
CA3047241A1 (en) | 2016-12-14 | 2018-06-21 | Progenity, Inc. | Ingestible device recovery system |
US20180168489A1 (en) | 2016-12-15 | 2018-06-21 | Progenity Inc. | Ingestible Device and Associated Methods |
DK3600009T3 (da) | 2017-03-31 | 2021-01-18 | Progenity Inc | Indretning, der kan indtages, med lokaliseringsegenskaber |
-
2017
- 2017-12-14 US US16/465,632 patent/US11597762B2/en active Active
- 2017-12-14 BR BR112019011702A patent/BR112019011702A2/pt not_active Application Discontinuation
- 2017-12-14 MX MX2019006823A patent/MX2019006823A/es unknown
- 2017-12-14 WO PCT/US2017/066474 patent/WO2018112232A1/en unknown
- 2017-12-14 CN CN202310488599.7A patent/CN117045784A/zh active Pending
- 2017-12-14 CN CN201780077480.3A patent/CN110072551B/zh active Active
- 2017-12-14 EP EP17826641.7A patent/EP3554540B1/en active Active
- 2017-12-14 CA CA3045475A patent/CA3045475A1/en active Pending
- 2017-12-14 JP JP2019531756A patent/JP7237834B2/ja active Active
- 2017-12-14 KR KR1020197019582A patent/KR20190095931A/ko not_active Application Discontinuation
-
2023
- 2023-03-01 JP JP2023030863A patent/JP2023071838A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CN110072551B (zh) | 2023-05-23 |
US20200262908A1 (en) | 2020-08-20 |
AU2017376807A1 (en) | 2019-06-13 |
EP3554540C0 (en) | 2023-08-02 |
CA3045475A1 (en) | 2018-06-21 |
CN117045784A (zh) | 2023-11-14 |
EP3554540B1 (en) | 2023-08-02 |
WO2018112232A1 (en) | 2018-06-21 |
JP2023071838A (ja) | 2023-05-23 |
US11597762B2 (en) | 2023-03-07 |
BR112019011702A2 (pt) | 2019-10-22 |
JP7237834B2 (ja) | 2023-03-13 |
JP2020501699A (ja) | 2020-01-23 |
KR20190095931A (ko) | 2019-08-16 |
CN110072551A (zh) | 2019-07-30 |
EP3554540A1 (en) | 2019-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019006823A (es) | Tratamiento de una enfermedad del tracto gastrointestinal con inhibidor de interleucina-12/interleucina-23 (il-12/il-23) liberado usando un dispositivo ingerible. | |
MX2019006867A (es) | Tratamiento de una enfermedad del tracto gastrointestinal con un inhibidor de integrina. | |
MX2019006864A (es) | Tratamiento de una enfermedad del tracto gastrointestinal con un inhibidor de factor de necrosis tumoral (tnf). | |
CY1122143T1 (el) | Φαρμακευτικοι συνδυασμοι που περιλαμβανουν εναν αναστολεα της b-raf, εναν αναστολεα του egfr και προαιρετικα εναν αναστολεα της ρι3κ-αλφα | |
MX2019006821A (es) | Tratamiento de una enfermedad del tracto gastrointestinal con un inhibidor de cinasa de janus (jak) y dispositivos. | |
MX2017015574A (es) | Inhibidores de tirosina quinasa de bruton. | |
WO2017091749A8 (en) | Shape changing drug delivery devices and methods | |
TW201613919A (en) | Inhibitors of Bruton's tyrosine kinase | |
PH12019500061A1 (en) | Oral gastroretentive formulations and uses thereof | |
PH12018502738A1 (en) | Compositions, devices, and methods for the treatment of alcohol use disorder | |
CY1119532T1 (el) | (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη | |
PH12018500254A1 (en) | Combinations of an ox40 antibody and a tlr4 modulator and uses thereof | |
CY1119522T1 (el) | (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη | |
MX2019005309A (es) | Anticuerpos anti-bag3 en combinacion con inhibidores del punto de control inmunitario para uso terapeutico. | |
EP3844168A4 (en) | COMBINATION DRUG PREPARATIONS FOR THE TREATMENT OF PATIENTS WITH CARDIOVASCULAR DISEASE AND ASSOCIATED CONDITIONS | |
CL2016003271A1 (es) | Métodos para tratar infecciones | |
TW201613926A (en) | Inhibitors of bruton's tyrosine kinase | |
IL271592A (en) | The compounds that combine an anti-inflammatory drug and the action of Dicer for the treatment of neurological diseases. | |
UA104615U (uk) | Спосіб лікування токсокарозу | |
UA111998U (uk) | Застосування декаметоксину як фармацевтично активної речовини для лікування захворювань шлунково-кишкового тракту та кишкових інфекцій перорально | |
EA201692163A1 (ru) | Лекарственное средство для лечения пациентов с тиннитусом | |
TH168817A (th) | อนุพันธ์อินโดลิซีนซึ่งเป็นสารยับยั้งฟอสโฟอิโนซิไทด์ 3-ไคเนส | |
UA91788U (uk) | Спосіб інтра- та післяопераційного введення гепатопротекторів при вогнищевих ураженнях печінки | |
UA101950U (uk) | Фармацевтична композиція для лікування і профілактики застуди | |
CN302310390S (zh) | 高电位治疗仪 |